| Prev Close | 41.99 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 30.89 / 57.41 |
| Avg Volume | 1.95M |
| Exchange | NYSE |
| Shares Outstanding | 2.55B |
| Market Cap | 107.51B |
| EPS | 2.00 |
| Div & Yield | 1.33 (3.10%) |
Latest News
Novo Nordisk And Glooko Advance Their Digital Health Collaboration With Launch Of Unique Integrated App For Improved Diabetes Management
Novo Nordisk makes the app available for free
Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices
The legislation would also force companies to announce planned price hikes.
Dow Holds Lower After House Passes Health Care Vote, Crude Falls
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANH, DVN, EXEL, FMC, FSI, GLT, MEOH, MJCO, MOH, NVO, RPXC, TECH, WU, WWE Downgrades: CIGI, IPHI, QUOT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Novo Nordisk Launches Xultophy® 100/3.6 (insulin Degludec And Liraglutide Injection) In The United States
- New combination treatment option for adults with type 2 diabetes now available in pharmacies
5 Things You Must Know Before the Market Opens Wednesday
U.S. stock futures decline and European shares trade lower following disappointing earnings from Apple and as Wall Street looks to Wednesday's announcement from the Federal Reserve on interest rates.
Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost
Novo Nordisk shares surged to a year-to-date high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook.
European Stocks Slump, Tech Sector Drifts After Apple's iPhone Miss Hits Suppliers
European stocks drifted lower as investors stepped back from a global market rally after disappointing earnings from Apple and weaker U.S. car sales put investors in a cautious mood.
Global Financial News: Apple Takes the Steam Out of the Global Equity Rally
European stocks slip as Apple earnings take the steam out of the global equity rally.
TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market
Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.
What to Expect From European Pharmaceuticals' First Quarter Results
New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.
Novo Nordisk Invites The Community To Unmask Everyday Heroes In Recognition Of World Hemophilia Day
#HemoHero stories to illustrate diverse experiences and inspiring acts of people affected by hemophilia
